Modern medical research shows that drug and surgical treatments for benign prostatic hyperplasia and chronic prostatitis carry high risks, while Dr Allen's Device, developed by Fine Treatment, an ...

Pfizer PFE reported positive top-line results from a late-stage study evaluating Talzenna (talazoparib), an oral PARP ...

This may not apply in your husband’s case, but it’s worth having the conversation. The two meds Goldstein prescribes for men are flibanserin (Addyi), an oral tablet taken d ...

What if a medicine you thought of as “old news” suddenly showed up in new research with fresh benefits that might stretch well beyond its original purpose? That’s exactly the twist happening with a ...

IN A LANDMARK decision, the Supreme Court of Appeal (SCA) in South Africa has ruled that the generic prostate cancer medication Enzutrix will remain available at an affordable price, ensuring access ...

Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

This new type of immunotherapy shows promise for treating different cancers including prostate cancer, leukaemia and lung ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." ...

Dr. Bertrand Tombal delivered a practical presentation titled “What Do You Need for Decision Making in mHSPC in 2026?”, focusing on how contemporary therapeutic choices in metastatic hormone-sensitive ...

Cardiovascular disease is the second leading cause of death among cancer survivors, second only to cancer itself. The same treatments that can save patients from cancer may also r ...